key: cord-0837116-agj5kxfm
authors: Ishii, Hiroshi; Nomura, Takushi; Yamamoto, Hiroyuki; Nishizawa, Masako; Thu Hau, Trang Thi; Harada, Shigeyoshi; Seki, Sayuri; Nakamura-Hoshi, Midori; Okazaki, Midori; Daigen, Sachie; Kawana-Tachikawa, Ai; Nagata, Noriyo; Iwata-Yoshikawa, Naoko; Shiwa, Nozomi; Suzuki, Tadaki; Park, Eun-Sil; Ken, Maeda; Onodera, Taishi; Takahashi, Yoshimasa; Kusano, Kohji; Shimazaki, Ryutaro; Suzaki, Yuriko; Ami, Yasushi; Matano, Tetsuro
title: Neutralizing antibody-independent SARS-CoV-2 control correlated with intranasal vaccine-induced CD8+ T-cell responses
date: 2022-01-19
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2022.100520
sha: ea1e7af9f361c4a7c0429c432b577dc1be793102
doc_id: 837116
cord_uid: agj5kxfm

Effective vaccines are essential for the control of the COVID-19 pandemic. Currently-developed vaccines inducing SARS-CoV-2 spike (S) antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared to nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced viral antigen-specific CD8+ T-cell responses. Our results indicate that CD8+ T-cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8+ T-cell responses to contribute to COVID-19 containment.

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 44 coronavirus 2 (SARS-CoV-2) has rapidly spread resulting in a pandemic. SARS-CoV-2 45 transmission that can occur from asymptomatic infected individuals is difficult to control. 1 However, reports on SARS-CoV-2 variants have recently been accumulated, and the 53 appearance of NAb-resistant S variant viruses is of great concern. 8-10 For example, B.1.351 (β 54 variant), a variant of concern (VOC), has shown reduced sensitivity to neutralization not only 55 by convalescent plasma of COVID-19 patients but also by plasma from vaccinated 56 individuals. [11] [12] [13] Hence, there is a demand for the development of a vaccine inducing effective 57 immune responses against these NAb-resistant variants. 14,15 58

While possible crossreactivity of vaccine-induced NAb responses to variants has been 59 indicated, [16] [17] [18] [19] induction of virus-specific T-cell responses may be an alternative vaccine 60 strategy to control VOC epidemics. Involvement of virus-specific T-cell responses in the control 61 of SARS-CoV-2 infection has been suggested. 20,21 Early induction of functional virus-specific 62 CD8 + T-cell responses has been observed in convalescent COVID-19 individuals, implying 63 contribution of CD8 + T cells in SARS-CoV-2 control. 22 Whereas CD8 + depletion in rhesus 64 macaques did not solely lead to viral control failure or severe disease progression in SARS-week 6 after the last vaccination. NME-specific CD4 + T-cell and CD8 + T-cell responses were 118 detectable just before challenge in five and three macaques, respectively ( Figure 1 ). None of 119 these vaccinated macaques induced anti-SARS-CoV-2 NAb responses before SARS-CoV-2 120 challenge (Table S2) . Four unvaccinated cynomolgus macaques (N031, N032, N041, and 121 N042) were also intranasally challenged with 10 5 TCID50 of SARS-CoV-2. Data on additional 122 five cynomolgus macaques intranasally infected with 10 5 TCID50 of the same SARS-CoV-2 123 stock in our previous study 23 were used as historical unvaccinated controls (Table S1) . 124

In the unvaccinated controls (n = 9), the geometric mean of viral RNA levels in 125 nasopharyngeal swabs on day 2 post-challenge was 1.1 x 10 8 copies/swab ( Figure 2A ). One 126 macaque N032 showed 5.6 x 10 5 copies/swab, but the remaining eight macaques had 6.9 x 10 7 127 ~ 1.1 x 10 9 copies/swab. In contrast, six of the seven vaccinated macaques showed less than 8.7 128

x 10 6 copies/swab of viral RNAs (Figure 2A ). Comparison revealed significantly lower viral 129 RNA levels in nasopharyngeal swabs on day 2 post-challenge in the vaccinated than the 130 unvaccinated macaques (p = 0.0311 by Mann-Whitney U test) ( Figure 2B ). Viral subgenomic 131 RNAs (sgRNAs) in nasopharyngeal swabs were detected on day 2 post-challenge in eight of 132 the nine unvaccinated controls but undetectable in six of the seven vaccinated macaques ( Figure  133 2C), exhibiting significant reduction in the viral sgRNA levels in the vaccinated macaques 134 compared to the unvaccinated controls (p = 0.0039 by Mann-Whitney U test) ( Figure 2D ). Virus 135 recovery from the nasopharyngeal swabs was consistent with viral RNA levels described above 136 ( Figure 2E ) and a significant reduction in viral titers on day 2 post-challenge was observed in 137 the vaccinated macaques compared to the unvaccinated (p = 0.0240 by Mann-Whitney U test) 138 ( Figure 2F ). These results indicate protective efficacy of the vaccination against intranasal 139 SARS-CoV-2 challenge. 140 responses 143

We then investigated immune correlates for this protective efficacy in the seven 144 vaccinated macaques. Remarkably, analysis revealed a significant inverse correlation between 145 viral RNA levels in nasopharyngeal swabs on day 2 post-challenge and NME-specific CD8 + T-146 cell responses 2 weeks after the last vaccination (p = 0.0040, r = -0.9550 by Spearman's test) 147 ( Figure 3A ). In contrast, no correlation was observed between the viral RNA levels and vaccine-148 induced NME-specific CD4 + T-cell responses. Further analysis showed significant inverse 149 correlation between viral RNA levels in nasopharyngeal swabs on day 2 post-challenge and 150 vaccine-induced N antigen-specific CD8 + T-cell responses which were predominant in vaccine-151 induced NME-specific CD8 + T-cell responses (p = 0.0254, r = -0.8365 by Spearman test) 152 ( Figure S3A ). We confirmed no significant correlation between the viral RNA levels and 153 vaccine-induced SeV-specific CD4 + T-cell or CD8 + T-cell responses ( Figure S3B were detectable in only one or two vaccinated macaques but undetectable in macaques V11 and 159 V12 that showed the top two lowest viral RNA levels in nasopharyngeal swabs on day 2 post-160 challenge ( Figures S2C and S2D ). Significant inverse correlation was observed between NME-161 specific CD8 + T-cell responses 2 weeks after the last vaccination and viral RNA levels in 162 nasopharyngeal swabs on day 5 (p = 0.0044, r = -0.9455 by Spearman test) but not on day 7 (p 163 = 0.0508, r = -0.7748 by Spearman test) post-challenge ( Figures S3E and S3F) . 164 Viral titers in nasopharyngeal swabs on day 2 post-challenge were also inversely 165 correlated with the vaccine-induced NME-specific CD8 + T-cell responses (p = 0.0071, r = -that exhibited the top three highest frequencies of vaccine-induced NME-specific CD8 + T cells 168 showed no virus recovery post-challenge ( Figure 2E ). 169

Analysis of tissues obtained at necropsy on day 7 or 9 post-challenge detected viral 170 sgRNA in the pharyngeal mucosa and/or retropharyngeal lymph nodes (RPLNs) of the four 171 unvaccinated controls (Table S3 ). It should be noted that sgRNA in the pharyngeal mucosa was 172 detected even in macaque N032, despite low viral RNA levels in nasopharyngeal swabs. In 173 contrast, viral sgRNA was undetectable in the pharyngeal mucosa and RPLNs in the three 174 vaccinated macaques (V11, V12, and V16) that exhibited the top three highest frequencies of 175 vaccine-induced NME-specific CD8 + T cells. Viral RNA levels in nasopharyngeal swabs on 176 day 7 post-challenge were greater than 10 5 copies/swab in all the unvaccinated macaques but 177 less than 10 4 copies/swab in these three vaccinated macaques ( Figure 2A ). Thus, in these three, 178 sgRNA was undetectable not only in nasopharyngeal swabs but also in the pharyngeal mucosa 179

and RPLNs obtained at necropsy (Table S3) . 180

Analysis using PBMCs on day 7 post-challenge detected NME-specific CD8 + T-cell 181 responses in five of the seven vaccinated macaques ( Figure 4A ). In contrast, analysis using 182 lymphocytes derived from the submandibular lymph nodes (SMLNs) obtained at necropsy on 183 day 7 or 9 post-challenge detected NME-specific CD8 + T-cell responses in all the seven 184 vaccinated macaques ( Figure 4B ). The NME-specific CD8 + T-cell frequencies in SMLNs in the 185 vaccinated were significantly higher than the four unvaccinated macaques (N031, N032, N041, 186 and N042) (p = 0.0394 by Mann-Whitney U test). NME-specific CD8 + T-cell responses in the 187 lung were detected in six vaccinated macaques except for V13 showing the highest viral RNA 188 level in the nasopharyngeal swab on day 2 ( Figure 4C ). was observed between vaccine-induced NME-specific CD8 + T-cell responses and viral RNA 210 levels in nasopharyngeal swabs on day 5 (p = 0.0044 in Figure S3E ) but not on day 7 (p = 211 0.0508; Figure S3F ). It may reflect the following two points. Vaccine-induced NME-specific CD8 + T-cell responses detected in PBMCs may not 219 directly work for the rapid viral control after the intranasal SARS-CoV-2 challenge. However, 220 our finding of the immuno-correlate might imply direct contribution of vaccine-induced 221 mucosal CD8 + T-cell responses around the pharyngeal mucosa to rapid viral control. It is 222 speculated that vaccine-induced peripheral NME-specific CD8 + T-cell responses around the 223 peak (rather than just before challenge) are indicative of efficient mucosal NME-specific CD8 In addition to the data on viral load in nasopharyngeal swabs, we had data on viral sgRNA 236 in the pharyngeal mucosa, RPLN, and the lung obtained at necropsy (Table S3 ). Viral sgRNA 237 in the lung was undetectable in all the unvaccinated and vaccinated macaques, while 238 bronchoalveolar lavage (BAL) was unexamined. Viral sgRNA in RPLN was detectable in three 239 of the four unvaccinated macaques but undetectable in all the seven vaccinated. Viral sgRNA 240 in the pharyngeal mucosa was detected in the four vaccinated macaques (V13, V14, V15, and 241 V17) with inefficient vaccine-induced NME-specific CD8 + T-cell responses, but undetectable in the three vaccinated macaques (V11, V12, and V16) that exhibited the top three highest 243 frequencies of vaccine-induced NME-specific CD8 + T cells, supporting our conclusion, 244 association of viral control with vaccine-induced CD8 + T-cell responses. These three vaccinated 245 macaques with efficient vaccine-induced NME-specific CD8 + T-cell responses controlled 246 SARS-CoV-2 replication without detectable virus recovery from nasopharyngeal swabs nor 247 sgRNAs in the pharyngeal mucosa. Although complete protection may be difficult, the rapid 248 reduction in nasopharyngeal viral load that was shown in the present study would be important 249 for inhibition of SARS-CoV-2 transmission from vaccinated but infected individuals, which 250 could be a key for the control of COVID-19 pandemic. 251 Viral sgRNAs were undetectable in the lung for all animals, regardless of vaccination 252 status, as described above (Table S3) Comparison of NME-specific CD8 + T-cell frequencies in PBMCs between U and V is shown 357 in the right panel. 358 (B) NME-specific CD4 + T-cell and CD8 + T-cell frequencies in SMLNs obtained at necropsy on 359 day 7 or 9 post-challenge. Comparison of NME-specific CD8 + T-cell frequencies in SMLNs 360 between U and V is shown in the right panel. Vaccinated macaques showed significantly higher 361 CD8 + T-cell frequencies compared to the unvaccinated controls (by Mann-Whitney U test). 362 (C) NME-specific CD4 + T-cell and CD8 + T-cell frequencies in the lung obtained at necropsy. 363

Comparison of NME-specific CD8 + T-cell frequencies in the lung between U and V is shown 364 in the right panel. (Table S1 ). The first group of three cynomolgus 409 macaques (V11, V12, and V13) received intramuscular vaccination with pcDNA-N (4 mg), wall thickening, interstitial infiltration of neutrophils, eosinophils, or mononuclear cells with 507 airspace macrophages, and/or lymphoid cell aggregation in bronchial associated lymphoid 508 tissue [BALT] or around blood vessels) was counted ( Figure S4 ). No severe bronchiolitis or 509 intestinal pulmonary inflammation was observed. 510

The implications of silent transmission for the control of COVID-19

BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-524 1273 SARS-CoV-2 Vaccine

ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 528 randomised controlled trials in Brazil, South Africa, and the UK

Safety and Efficacy of Single

Dose Ad26.COV2.S Vaccine against Covid-19

SARS-CoV-534 2 neutralizing antibody structures inform therapeutic strategies

Recognition of the SARS-CoV-2 536 receptor binding domain by neutralizing antibodies

variant of concern in South Africa

Emergence and 543 rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Novel SARS-CoV-2 variants: the pandemics within 546 the pandemic

Evidence of escape of SARS

CoV-2 variant B.1.351 from natural and vaccine-induced sera

SARS-CoV-2 variants

1.351 and P.1 escape from neutralizing antibodies

Antibody resistance of SARS-CoV-2 variants B.1.351 and 555

SARS-CoV-2 Variants and

Progress 560 of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, 561 effectiveness and escape

Durability of mRNA-1273 vaccine-567 induced antibodies against SARS-CoV-2 variants

Two doses of the SARS

CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with 571 prior SARS-CoV-2 infection

Protective efficacy 574 of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Broad and strong memory CD4 + and CD8 + T cells induced 577 by SARS-CoV-2 in UK convalescent individuals following COVID-19

Antigen-Specific

Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and 582

SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell

Correlates of protection against SARS-CoV-597 2 in rhesus macaques

Single-shot Ad26 vaccine protects 600 against SARS-CoV-2 in rhesus macaques

A modified 603 vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, 604 immune pathology, and dysfunction in the lungs

Immunogenicity of

S vaccine against SARS-CoV-2 variants in humans

Rapid induction of antigen-610 specific CD4 + T cells is associated with coordinated humoral and cellular immune 611 responses to SARS-CoV-2 mRNA vaccination

Heterologous prime-boost vaccination

Enhanced isolation of SARS-CoV-2 by

TMPRSS2-expressing cells

Protective efficacy of an AIDS vaccine, a single DNA-prime 622 followed by a single booster with a recombinant replication-defective Sendai virus vector, 623 in a macaque AIDS model

Evaluation of the immunogenicity of 626 replication-competent V-knocked-out and replication-defective F-deleted Sendai virus 627 vector-based vaccines in macaques

A cytoplasmic RNA vector derived from

nontransmissible Sendai virus with efficient gene transfer and expression

A Novel Immunogen Selectively Eliciting CD8 + T Cells 634 but Not CD4 + T Cells Targeting Immunodeficiency Virus Antigens

Temporal maturation of neutralizing 647 antibodies in COVID-19 convalescent individuals improves potency and breadth to 648 circulating SARS-CoV-2 variants